Related stories
Roivant Reports $35.1 Million Revenue and $191.6 Million Net Loss
Roivant reported the results for the second quarter ended September 30, 2026. The quarter included the U.S. launch of LISRAYA and progress across several clinical programs; consoli
M impact | EARNINGS | Nov 09, 2026, 12:23 PM UTC
Hain Celestial Q1 Sales Miss Estimates
L impact | EARNINGS | Nov 09, 2026, 12:18 PM UTC
Kaspi.kz 3Q E-Commerce Revenue Rose 23% to KZT343B
Unaudited 3Q 2026 results showed constant-currency e-Commerce revenue up 23% to KZT343B and Marketplace constant-currency GMV up 8% to KZT2.2T. The Board proposed a quarterly divid
M impact | EARNINGS | Nov 09, 2026, 12:17 PM UTC
Superior Group Q3 Sales Beat Estimates; Outlook Tightened
M impact | EARNINGS | Nov 09, 2026, 12:15 PM UTC
TG Therapeutics Raises 2026 Revenue Guidance to About $1 Billion
TG Therapeutics reported third-quarter 2026 revenue of $259.9 million and net income of $55.5 million. It raised its 2026 global revenue target to approximately $1 billion and its
M impact | EARNINGS | Nov 09, 2026, 12:15 PM UTC
US Futures Rebound from Friday Plunge
US equities were set to rebound on Monday from their selloff last session as markets reconsidered risks of slower spending on AI and infrastructure. Futures tied to the S&P 500 add
H impact | EARNINGS | Nov 09, 2026, 12:09 PM UTC